TrialCNS neuroscience & therapeutics2013
BCL2A1 is a potential biomarker for postoperative seizure control in patients with low-grade gliomas.
Gan You et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this paperpooled itcites it